Skip to content

Turmeric tonic in the management of scalp psoriasis; a clinical double blind, placebo controlled evaluation

Turmeric tonic in the management of scalp psoriasis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201604183106N30
Enrollment
40
Registered
2016-11-10
Start date
2015-12-30
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis. Psoriasis

Interventions

Treatment - Drugs
Placebo
Intervention 1: Apply Curcumin tonic topcally twice a day for 9 weeks. Intervention 2: Apply placebo topically twice a day for 9 weeks.
Apply Curcumin tonic topcally twice a day for 9 weeks.
Apply placebo topically twice a day for 9 weeks

Sponsors

Islamic Azad University Pharmaceutical branch and Self supported
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Definitive diagnosis of mild to moderate scalp psoriasis; Patient age 18-75 with no limitation in gender; Lack of infections or malignancies on scalp skin; Two weeks Wash out period topical and one month systemic anti psoriasis treatment; Patient agreement to participate in the clinical trial Exclusion criteria: Pregnancy; Lactation; Allergy or irritation to any component of formulation

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Redness. Timepoint: Week 0 (baseline), week 3 , 6 , 9 to complete the follow up. Method of measurement: 1.Psoriasis questionnaire 2.Psoriasis quality of life questionnaire 3. photography: before, during and aftertreatment 4. PASI calculator.;Thickness. Timepoint: Week 0 (baseline), week 3 , 6 , 9 to complete the follow up. Method of measurement: 1.Psoriasis questionnaire 2.Psoriasis quality of life questionnaire 3. photography: before, during and after treatment 4. PASI calculator.;Scaling. Timepoint: Week 0 (baseline), week 3 , 6 , 9 to complete the follow up. Method of measurement: 1.Psoriasis questionnaire 2.Psoriasis quality of life questionnaire 3. photography: before, during and after treatment 4. PASI calculator.;Involved area. Timepoint: Week 0 (baseline), week 3 , 6 , 9 to complete the follow up. Method of measurement: 1.Psoriasis questionnaire 2.Psoriasis quality of life questionnaire 3. photography: before, during and after treatment 4. PASI calculator.;PASI score. Timepoint: Week 0 (baseline), week 3 , 6 , 9 to complete the follow up. Method of measurement: PASI calculator.;Photography. Timepoint: Week 0 (baseline), week 3 , 6 , 9 to complete the follow up. Method of measurement: photography: before, during and after treatment.

Secondary

MeasureTime frame
Reported side effects (systemic and local). Timepoint: Patients were given a telephone number to call during treatment. Patient could report any side effects as well as during follow up, all the way through the treatment and after completion. Method of measurement: Patients were given a telephone number to call during treatment. Patient could report any side effects as well as during followup, all the way through the treatment and after completion.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mehdi Rajabi

Islamic Azad University Pharmaceutical Sciences branch

mehdirj@aol.co.uk+98 21 2264 0051

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026